{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:43:21Z","timestamp":1780469001208,"version":"3.54.1"},"reference-count":89,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,6,18]],"date-time":"2023-06-18T00:00:00Z","timestamp":1687046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Recent developments aim to extend the cytotoxic effect and therapeutic window of mAbs by constructing antibody\u2013drug conjugates (ADCs), in which the targeting moiety is the mAb that is linked to a highly toxic drug. According to a report from mid of last year, the global ADCs market accounted for USD 1387 million in 2016 and was worth USD 7.82 billion in 2022. It is estimated to increase in value to USD 13.15 billion by 2030. One of the critical points is the linkage of any substituent to the functional group of the mAb. Increasing the efficacy against cancer cells\u2019 highly cytotoxic molecules (warheads) are connected biologically. The connections are completed by different types of linkers, or there are efforts to add biopolymer-based nanoparticles, including chemotherapeutic agents. Recently, a combination of ADC technology and nanomedicine opened a new pathway. To fulfill the scientific knowledge for this complex development, our aim is to write an overview article that provides a basic introduction to ADC which describes the current and future opportunities in therapeutic areas and markets. Through this approach, we show which development directions are relevant both in terms of therapeutic area and market potential. Opportunities to reduce business risks are presented as new development principles.<\/jats:p>","DOI":"10.3390\/pharmaceutics15061761","type":"journal-article","created":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T01:59:51Z","timestamp":1687139991000},"page":"1761","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Business Risk Mitigation in the Development Process of New Monoclonal Antibody Drug Conjugates for Cancer Treatment"],"prefix":"10.3390","volume":"15","author":[{"given":"Bal\u00e1zs","family":"Kiss","sequence":"first","affiliation":[{"name":"Faculty of Economics, University of Debrecen, 4032 Debrecen, Hungary"},{"name":"BBS Dominus LLC, 4225 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2395-9516","authenticated-orcid":false,"given":"J\u00e1nos","family":"Borb\u00e9ly","sequence":"additional","affiliation":[{"name":"Doctoral School of Clinical Medicine, University of Debrecen, 4032 Debrecen, Hungary"},{"name":"BBS Biochemicals LLC, 4225 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Fernald, K.D.S., Pennings, H.P.G., Bosch, J.F.V.D., Commandeur, H.R., and Claassen, E. (2017). The moderating role of absorptive capacity and the differential effects of acquisitions and alliances on Big Pharma firms\u2019 innovation performance. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0172488"},{"key":"ref_2","unstructured":"(2017, July 24). Bayer ADC Fails Pivotal Mesothelioma Trial. Available online: https:\/\/www.fiercebiotech.com\/biotech\/bayer-adc-fails-pivotal-mesothelioma-trial."},{"key":"ref_3","unstructured":"(2023, March 13). Pfizer Invests $43 Billion to Battle Cancer. Available online: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-invests-43-billion-battle-cancer."},{"key":"ref_4","unstructured":"(2023, March 13). With $43B Buyout, Pfizer Sees Cancer Specialist Seagen as a \u2018Goose\u2019 Laying \u2018Golden Eggs\u2019. Available online: https:\/\/www.fiercepharma.com\/pharma\/43b-buyout-pfizer-sees-seagen-its-golden-goose."},{"key":"ref_5","unstructured":"(2023, January 26). After Dose De-Escalation, Death Drives Magenta to Pause Antibody-Drug Conjugate Leukemia Trial. Available online: https:\/\/www.fiercebiotech.com\/biotech\/after-dose-de-escalation-death-drives-magenta-pause-antibody-drug-conjugate-leukemia-trial."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrd3980","article-title":"Antibody\u2013drug conjugates","volume":"12","author":"Zolot","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"10732748221142945","DOI":"10.1177\/10732748221142945","article-title":"Cost-Effectiveness Analysis of CAR T-Cell Therapies vs Antibody Drug Conjugates for Patients with Advanced Multiple Myeloma","volume":"30","author":"Kapinos","year":"2023","journal-title":"Cancer Control."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Mckertish, C.M., and Kayser, V. (2021). Advances and Limitations of Antibody Drug Conjugates for Cancer. Biomedicines, 9.","DOI":"10.3390\/biomedicines9080872"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s40164-022-00347-1","article-title":"Learn from antibody\u2013drug conjugates: Consideration in the future construction of peptide-drug conjugates for cancer therapy","volume":"11","author":"Wu","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1158\/0008-5472.CAN-15-1518","article-title":"Dual HER2 Targeting with Trastuzumab and Liposomal-Encapsulated Doxorubicin (MM-302) Demonstrates Synergistic Antitumor Activity in Breast and Gastric Cancer","volume":"76","author":"Espelin","year":"2016","journal-title":"Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1907906","DOI":"10.1002\/adfm.201907906","article-title":"Bio-Conjugated Advanced Materials for Targeted Disease Theranostics","volume":"30","author":"Hu","year":"2020","journal-title":"Adv. Funct. Mater."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4147","DOI":"10.1038\/s41598-020-60856-z","article-title":"Prototyping Trastuzumab Docetaxel Immunoliposomes with a New FCM-Based Method to Quantify Optimal Antibody Density on Nanoparticles","volume":"10","author":"Rodallec","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"118605","DOI":"10.1016\/j.ijpharm.2019.118605","article-title":"EGFR-targeted immunoliposomes as a selective delivery system of simvastatin, with potential use in treatment of triple-negative breast cancers","volume":"569","author":"Matusewicz","year":"2019","journal-title":"Int. J. Pharm."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Juan, A., Cimas, F.J., Bravo, I., Pandiella, A., Oca\u00f1a, A., and Alonso-Moreno, C. (2020). Antibody Conjugation of Nanoparticles as Therapeutics for Breast Cancer Treatment. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21176018"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"100365","DOI":"10.1016\/j.esmoop.2021.100365","article-title":"Targeting immunoliposomes to EGFR-positive glioblastoma","volume":"7","author":"Kasenda","year":"2022","journal-title":"ESMO Open"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1038\/s41598-023-30950-z","article-title":"A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer","volume":"13","author":"Mamot","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.colsurfb.2016.10.044","article-title":"Folic Acid and Trastuzumab Conjugated Redox Responsive Random Multiblock Copolymeric Nanocarriers for Breast Cancer Therapy: In-Vitro and in-Vivo Studies","volume":"149","author":"Kumar","year":"2017","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Peng, J., Chen, J., Xie, F., Bao, W., Xu, H., Wang, H., Xu, Y., and Du, Z. (2019). Herceptin-Conjugated Paclitaxel Loaded PCL-PEG Worm-like Nanocrystal Micelles for the Combinatorial Treatment of HER2-Positive Breast Cancer. Biomaterials, 222.","DOI":"10.1016\/j.biomaterials.2019.119420"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"101136","DOI":"10.1016\/j.jddst.2019.101136","article-title":"Active Targeting Carrier for Breast Cancer Treatment: Monoclonal Antibody Conjugated Epirubicin Loaded Nanoparticle","volume":"53","author":"Kolahkaj","year":"2019","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"115206","DOI":"10.1016\/j.carbpol.2019.115206","article-title":"Doxorubicin\/Cisplatin Co-Loaded Hyaluronic Acid\/Chitosan-Based Nanoparticles for in Vitro Synergistic Combination Chemotherapy of Breast Cancer","volume":"225","author":"Wang","year":"2019","journal-title":"Carbohydr. Polym."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1080\/10837450.2019.1709500","article-title":"Herceptin-Decorated Paclitaxel-Loaded Poly(Lactide-Co-Glycolide) Nanobubbles: Ultrasound-Facilitated Release and Targeted Accumulation in Breast Cancers","volume":"25","author":"Zhong","year":"2020","journal-title":"Pharm. Dev. Technol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1021\/la504870f","article-title":"Dendrimer nanofluids in the concentrated regime: From polymer melts to soft spheres","volume":"31","author":"Pilkington","year":"2015","journal-title":"Langmuir"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Choi, J.-H., Gu, H.-J., Park, K.-H., Hwang, D.-S., and Kim, G.-C. (2022). Anti-Cancer Activity of the Combinational Treatment of Noozone Cold Plasma with p-FAK Antibody-Conjugated Gold Nanoparticles in OSCC Xenograft Mice. Biomedicines, 10.","DOI":"10.3390\/biomedicines10092259"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Lodhi, M.S., Khalid, F., Khan, M.T., Samra, Z.Q., Muhammad, S., Zhang, Y.-J., and Mou, K. (2022). A Novel Method of Magnetic Nanoparticles Functionalized with Anti-Folate Receptor Antibody and Methotrexate for Antibody Mediated Targeted Drug Delivery. Molecules, 27.","DOI":"10.3390\/molecules27010261"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/d41573-021-00018-6","article-title":"The breast cancer drug market","volume":"20","author":"Wilcock","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_26","unstructured":"(2022, June 21). Antibody Drug Conjugate Market, a $13.15 billion Industry by 2030 with a CAGR of 14.12%. Available online: https:\/\/www.globenewswire.com\/en\/news-release\/2022\/06\/21\/2465821\/0\/en\/Antibody-Drug-Conjugate-Market-a-13-15-billion-Industry-by-2030-with-a-CAGR-of-14-12.html."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/d41573-021-00054-2","article-title":"The oncology market for antibody\u2013drug conjugates","volume":"20","author":"Pazo","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_28","unstructured":"(2022, December 27). Antibody-Drug Conjugates (ADCs) List Approved by FDA (2000\u20132023). Available online: https:\/\/axispharm.com\/antibody-drug-conjugatesadcs-list-approved-by-fda2000-2022\/."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Afzal, O., Altamimi, A.S.A., Nadeem, M.S., Alzarea, S.I., Almalki, W.H., Tariq, A., Mubeen, B., Murtaza, B.N., Iftikhar, S., and Riaz, N. (2022). Nanoparticles in Drug Delivery: From History to Therapeutic Applications. Nanomaterials, 12.","DOI":"10.3390\/nano12244494"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Roma-Rodrigues, C., Rivas-Garc\u00eda, L., Baptista, P.V., and Fernandes, A.R. (2020). Gene Therapy in Cancer Treatment: Why Go Nano?. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12030233"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"400","DOI":"10.7150\/ntno.74613","article-title":"Nanotechnology Advances in the Detection and Treatment of Cancer: An Overview","volume":"6","author":"Abbasi","year":"2022","journal-title":"Nanotheranostics"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Nakamura, T., Yamada, Y., Sato, Y., Khalil, I.A., and Harashima, H. (2019). Innovative nanotechnologies for enhancing nucleic acids\/gene therapy: Controlling intracellular trafficking to targeted biodistribution. Biomaterials, 218.","DOI":"10.1016\/j.biomaterials.2019.119329"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Chizenga, E.P., and Abrahamse, H. (2020). Nanotechnology in Modern Photodynamic Therapy of Cancer: A Review of Cellular Resistance Patterns Affecting the Therapeutic Response. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12070632"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1002\/viw2.6","article-title":"Application of nanotechnology for enhancing photodynamic therapy via ameliorating, neglecting, or exploiting tumor hypoxia","volume":"1","author":"Hu","year":"2020","journal-title":"View"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41568-019-0186-9","article-title":"Improving cancer immunotherapy through nanotechnology","volume":"19","author":"Goldberg","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Akk\u0131n, S., Varan, G., and Bilensoy, E. (2021). A Review on Cancer Immunotherapy and Applications of Nanotechnology to Chemoimmunotherapy of Different Cancers. Molecules, 26.","DOI":"10.3390\/molecules26113382"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e1576","DOI":"10.1002\/wnan.1576","article-title":"Advances of nanotechnology in osteochondral regeneration","volume":"11","author":"Deng","year":"2019","journal-title":"WIREs Nanomed. Nanobiotechnol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"101617","DOI":"10.1016\/j.jddst.2020.101617","article-title":"Advances in nanotechnology and nanomaterials based strategies for neural tissue engineering","volume":"57","author":"Kumar","year":"2020","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.21873\/anticanres.13359","article-title":"Synthesis of 68Ga-Labeled Biopolymer-based Nanoparticle Imaging Agents for Positron-emission Tomography","volume":"39","author":"Hajdu","year":"2019","journal-title":"Anticancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"122462","DOI":"10.1016\/j.ijpharm.2022.122462","article-title":"In vivo assessment of tumor targeting potential of 68Ga-labelled randomly methylated beta-cyclodextrin (RAMEB) and 2-hydroxypropyl-\u03b2-cyclodextrin (HP\u03b2CD) using positron emission tomography","volume":"630","author":"Csige","year":"2023","journal-title":"Int. J. Pharm."},{"key":"ref_42","first-page":"49","article-title":"Tumor-specific Localization of Self-assembled Nanoparticle PET\/MR Modalities","volume":"34","author":"Hajdu","year":"2014","journal-title":"Anticancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.2967\/jnumed.122.263895","article-title":"Nanoparticle diagnostics and theranostics in the clinic","volume":"63","author":"Pallares","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Luo, D., Wang, X., Burda, C., and Basilion, J.P. (2021). Recent development of gold nanoparticles as contrast agents for cancer diagnosis. Cancers, 13.","DOI":"10.3390\/cancers13081825"},{"key":"ref_45","unstructured":"Grand View Research (2023, March 13). Nanomedicine Market Size, Share & Trends Analysis Report by Product (Therapeutics, Diagnostics), by Application (Oncology, Infectious Diseases), by Region, and Segment Forecasts, 2021\u20132028. Report ID: 978-1-68038-942-5. Available online: https:\/\/www.grandviewresearch.com\/industry-analysis\/nanomedicine-market."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.addr.2019.06.003","article-title":"Nanomedicines\u2014Tiny particles and big challenges","volume":"151\u2013152","author":"Marques","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/bs.acr.2021.07.006","article-title":"Chapter Eight\u2014Targeting The \u201cUndruggable\u201d RAS with Biologics","volume":"Volume 153","author":"Whaby","year":"2022","journal-title":"Advances in Cancer Research"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1021\/acs.bioconjchem.2c00024","article-title":"Evaluation of Cellular Targeting by Fab\u2032 vs Full-Length Antibodies in Antibody\u2013Nanoparticle Conjugates (ANCs) Using CD4 T-cells","volume":"33","author":"Singh","year":"2022","journal-title":"Bioconjugate Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ddtec.2018.10.003","article-title":"Antibody conjugated nanoparticles as a novel form of antibody drug conjugate chemotherapy","volume":"30","author":"Johnston","year":"2018","journal-title":"Drug Discov. Today Technol."},{"key":"ref_50","first-page":"5628","article-title":"Antibody\u2013drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes","volume":"234","author":"Lotfinia","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"13613","DOI":"10.1039\/D1SC02973H","article-title":"Recent developments in chemical conjugation strategies targeting native amino acids in proteins and their applications in antibody\u2013drug conjugates","volume":"12","author":"Kang","year":"2021","journal-title":"Chem. Sci."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Oltolina, F., Colangelo, D., Miletto, I., Clemente, N., Miola, M., Vern\u00e9, E., Prat, M., and Follenzi, A. (2019). Tumor Targeting by Monoclonal Antibody Functionalized Magnetic Nanoparticles. Nanomaterials, 9.","DOI":"10.3390\/nano9111575"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"\u017belechowska-Matysiak, K., Wawrowicz, K., Wierzbicki, M., Budlewski, T., Bilewicz, A., and Majkowska-Pilip, A. (2023). Doxorubicin- and Trastuzumab-Modified Gold Nanoparticles as Potential Multimodal Agents for Targeted Therapy of HER2+ Cancers. Molecules, 28.","DOI":"10.3390\/molecules28062451"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Zumaya, A.L.V., Rimpelov\u00e1, S., \u0160t\u011bjd\u00ed\u0159ov\u00e1, M., Ulbrich, P., Vil\u010d\u00e1kov\u00e1, J., and Hassouna, F. (2022). Antibody Conjugated PLGA Nanocarriers and Superparmagnetic Nanoparticles for Targeted Delivery of Oxaliplatin to Cells from Colorectal Carcinoma. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031200"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Ioele, G., Chieffallo, M., Occhiuzzi, M.A., De Luca, M., Garofalo, A., Ragno, G., and Grande, F. (2022). Anticancer Drugs: Recent Strategies to Improve Stability Profile, Pharmacokinetic and Pharmacodynamic Properties. Molecules, 27.","DOI":"10.3390\/molecules27175436"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","article-title":"Antibody\u2013Drug Conjugates: A Comprehensive Review","volume":"18","author":"Khongorzul","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.drudis.2021.09.015","article-title":"Factors influencing the choice of monoclonal antibodies for antibody\u2013drug conjugates","volume":"27","author":"Hasan","year":"2021","journal-title":"Drug Discov. Today"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1158\/0008-5472.CAN-19-2295","article-title":"Increased Tumor Penetration of Single-Domain Antibody\u2013Drug Conjugates Improves In Vivo Efficacy in Prostate Cancer Models","volume":"80","author":"Nessler","year":"2020","journal-title":"Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s00216-019-01633-4","article-title":"Nanobody: Outstanding features for diagnostic and therapeutic applications","volume":"411","author":"Salvador","year":"2019","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.tibtech.2017.04.007","article-title":"Affibody Molecules in Biotechno-logical and Medical Applications","volume":"35","author":"Frejd","year":"2017","journal-title":"Trends Biotechnol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13045-022-01397-y","article-title":"Payload diversification: A key step in the development of antibody\u2013drug conjugates","volume":"16","author":"Conilh","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"6974","DOI":"10.1002\/anie.200900942","article-title":"Bioorthogonal Chemistry: Fishing for Selectivity in a Sea of Functionality","volume":"48","author":"Sletten","year":"2009","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1039\/C8CS00676H","article-title":"Cleavable linkers in antibody\u2013drug conjugates","volume":"48","author":"Bargh","year":"2019","journal-title":"Chem. Soc. Rev."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1080\/19420862.2018.1512327","article-title":"Antibody-drug conjugate library prepared by scanning insertion of the aldehyde tag into IgG1 constant regions","volume":"10","author":"Huang","year":"2018","journal-title":"mAbs"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s12935-022-02679-8","article-title":"Potential of antibody\u2013drug conjugates (ADCs) for cancer therapy","volume":"22","author":"Marei","year":"2022","journal-title":"Cancer Cell Int."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","article-title":"Antibody-drug conjugates: Recent advances in conjugation and linker chemistries","volume":"9","author":"Tsuchikama","year":"2016","journal-title":"Protein Cell"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jddst.2018.10.026","article-title":"Crosslinked poly-\u03b3-glutamic acid based nanosystem for drug delivery","volume":"48","author":"Fazekas","year":"2018","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_68","first-page":"715","article-title":"Biopolymer based nanosystem for doxorubicin targeted delivery","volume":"7","author":"Kerekes","year":"2017","journal-title":"Am. J. Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Marques, A.C., Costa, P.C., Velho, S., and Amaral, M.H. (2023). Lipid Nanoparticles Functionalized with Antibodies for Anticancer Drug Therapy. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15010216"},{"key":"ref_70","unstructured":"(2022, May 23). Aptamer Group and PinotBio Extend Collaboration for the Development of Optimer-Drug Conjugates. Available online: https:\/\/aptamergroup.com\/aptamer-group-and-pinotbio-extend-collaboration-for-the-development-of-optimer-drug-conjugates\/."},{"key":"ref_71","unstructured":"(2022, May 23). Aptamer Group and PinotBio Extend Collaboration. Available online: https:\/\/markets.ft.com\/data\/announce\/detail?dockey=1323-15463214-6M6DQKFL242JNP55NP7RKRB7S6."},{"key":"ref_72","unstructured":"(2022, June 10). ADC Therapeutics Announces Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) in Relapsed or Refractory Hodgkin Lymphoma. Available online: https:\/\/ir.adctherapeutics.com\/press-releases\/press-release-details\/2022\/ADC-Therapeutics-Announces-Results-from-Pivotal-Phase-2-Clinical-Trial-of-Camidanlumab-Tesirine-Cami-in-Relapsed-or-Refractory-Hodgkin-Lymphoma\/default.aspx."},{"key":"ref_73","unstructured":"(2022, June 14). Spirea Raises \u00a32.4M in Funding. Available online: https:\/\/www.finsmes.com\/2022\/06\/spirea-raises-2-4m-in-funding.html."},{"key":"ref_74","unstructured":"(2022, November 05). FDA Grants Regular Approval to Fam-Trastuzumab Deruxtecan-Nxki for Breast Cancer, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-regular-approval-fam-trastuzumab-deruxtecan-nxki-breast-cancer."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.yrtph.2017.10.021","article-title":"Aligning nanotoxicology with the 3Rs: What is needed to realise the short, medium and long-term opportunities?","volume":"91","author":"Burden","year":"2017","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/j.1748-720X.2012.00709.x","article-title":"Concepts of Risk in Nanomedicine Research","volume":"40","author":"Hogle","year":"2012","journal-title":"J. Law Med. Ethics"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3389\/fphar.2018.00228","article-title":"Risk assessment and risk minimization in nanomedicine: A need for predictive, alternative, and 3Rs strategies","volume":"9","author":"Accomasso","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12967-016-0838-4","article-title":"Changing R & D models in research-based pharmaceutical companies","volume":"14","author":"Schuhmacher","year":"2016","journal-title":"J. Transl. Med."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Domonkos, D., and Hronszki, I. (2012). Risk Assessment of Innovations in The Biopharmaceutical Industry\/Book 2, IntechOpen.","DOI":"10.5772\/38787"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Baah, S., Laws, M., and Rahman, K.M. (2021). Antibody\u2013Drug Conjugates\u2014A Tutorial Review. Molecules, 26.","DOI":"10.3390\/molecules26102943"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: The \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.14694\/EdBook_AM.2013.33.e103","article-title":"Picking the Optimal Target for Antibody-Drug Conjugates","volume":"33","author":"Mathur","year":"2013","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_83","unstructured":"Haubenreisser, S. (2014, January 14\u201315). EMA perspective on the development of Nanomedicines. Proceedings of the PQRI Nanotechnology Workshop, Washington, DC, USA."},{"key":"ref_84","first-page":"1005","article-title":"Nanotherapeutics in the EU: An overview on current state and future directions","volume":"9","author":"Hafner","year":"2014","journal-title":"Int. J. Nanomed."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Hardison, S. (2021). Oncology Dealmaking in 2020. Biopharm. Deal., B5. Available online: https:\/\/www.nature.com\/articles\/d43747-021-00024-y.","DOI":"10.1038\/d43747-021-00024-y"},{"key":"ref_86","unstructured":"Sambandan, P., and Raja, H.B. (2015). Open Innovation in Pharmaceutical Industry, a Case Study of Eli Lilly: How Do Big Pharmas Implement OI?\u2014A Critical Analysis of the Current OI Practices through a Case Study. [Master\u2019s Thesis, Department of Industrial Economics and Management (INDEK), KTH School of Industrial Engineering and Management (ITM)]."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.respol.2017.06.005","article-title":"The rise of project network organizations: Building core teams and flexible partner pools for interorganizational projects","volume":"46","author":"Manning","year":"2017","journal-title":"Res. Policy"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Tong, J.T.W., Harris, P.W.R., Brimble, M.A., and Kavianinia, I. (2021). An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy. Molecules, 26.","DOI":"10.3390\/molecules26195847"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Damelin, M. (2018). Innovations for Next-Generation Antibody-Drug Conjugates, Humana Press.","DOI":"10.1007\/978-3-319-78154-9"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/6\/1761\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:56:00Z","timestamp":1760126160000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/6\/1761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,18]]},"references-count":89,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["pharmaceutics15061761"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics15061761","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,18]]}}}